| Patent application number | Description | Published |
|---|
| 20090012295 | Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib - The present invention provides amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib. | 01-08-2009 |
| 20090118297 | POLYMORPHS OF DASATINIB AND PROCESS FOR PREPARATION THEREOF - Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof. | 05-07-2009 |
| 20090124642 | Crystalline forms of Erlotinib HCI and formulations thereof - The invention provides a novel crystalline form of Erlotinib HCl, processes for its preparation, and formulations thereof. | 05-14-2009 |
| 20090192200 | POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF - Provided are sorafenib hemi-tosylate, polymorphs thereof, polymorphs of sorafenib tosylate, preparation thereof and pharmaceutical compositions thereof. | 07-30-2009 |
| 20100004449 | CRYSTALLINE FORMS OF ERLOTINIB BASE AND ERLOTINIB HCL - The preparation of crystalline Erlotinib base form G2 is described. This crystalline form can be converted to an Erlotinib salt, such as Erlotinib HCl, which can be used in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). | 01-07-2010 |
| 20110118477 | SUNITINIB AND SALTS THEREOF AND THEIR POLYMORPHS - Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate. | 05-19-2011 |
